All eyes on a hurdle race for a SARS-CoV-2 vaccine.

@article{Gaebler2020AllEO,
  title={All eyes on a hurdle race for a SARS-CoV-2 vaccine.},
  author={Christian Gaebler and Michel C. Nussenzweig},
  journal={Nature},
  year={2020},
  volume={586 7830},
  pages={
          501-502
        }
}
economic impact of COVID-19, together with the absence of any clearly effective preventive or therapeutic remedies, has created a massive unmet medical need. Rapid responses by governments, academia and industry have already resulted in the production of more than 180 vaccine candidates (see page 516), 42 of which are being tested in humans at the time of writing. The considerable design flexibility of newer types of vaccine technology gave these candidates a head start in the race. Some of the… 
COVID-19 Vaccine Race: An Overview and Update
TLDR
The overview of the possible types of vaccines against Covid-19 as well as a glimpse of vaccine race with different phases of clinical trial data, comparison of the rate of success of phase-III clinical trials and their safety, and drawbacks with the present status are reported.
COVID-19 Vaccines: Current Conditions and Future Prospects
TLDR
An overview of the current SARS-CoV-2 vaccines with their mechanisms of action, current technologies utilized in manufacturing of the vaccines, and limitations in this new field with emerging data is provided.
COVID-19 Vaccine: Critical Questions with Complicated Answers
TLDR
Few important questions regarding SARS-CoV-2 vaccine development are explored in this review, but an effective and safe vaccine could play a pivotal role in eradicating COVID-19.
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants
TLDR
The results suggest that the monoclonal antibodies in clinical use should be tested against newly arising variants, and that mRNA vaccines may need to be updated periodically to avoid potential loss of clinical efficacy.
The Genetic Variant of SARS-CoV-2: would It Matter for Controlling the Devastating Pandemic?
TLDR
This review summarized the current understanding on five notable genetic variants, i.e., D614G, Cluster 5, VOC 202012/01, 501Y.V2 and P.1, and discussed the potential impact of these variants on the virus transmission, pathogenesis and vaccine efficacy.
First computational design using lambda-superstrings and in vivo validation of SARS-CoV-2 vaccine
TLDR
It is concluded that it is a valid method to decipher the best epitopes of the Spike protein of SARS-CoV-2 to prepare peptide-based vaccines for different vector platforms, including DC vaccines.
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants.
TLDR
The results suggest that the monoclonal antibodies in clinical use should be tested against newly arising variants, and that mRNA vaccines may need to be updated periodically to avoid potential loss of clinical efficacy.
The BioNTech / Pfizer vaccine BNT162b2 induces class-switched SARS-CoV-2-specific plasma cells and potential memory B cells as well as IgG and IgA serum and IgG saliva antibodies upon the first immunization
TLDR
The data suggest that the vaccine induces a promising CD4+ T cell-dependent systemic IgG1 and IgG3 Ab response with IgG+ PCs and potential memory B cells, which might help to improve a first line of defense in the respiratory tract against SARS-CoV-2 and its mutants.
How Will Emerging SARS-CoV-2 Variants Impact Herd Immunity?
TLDR
The impact of these emerging SARS-CoV-2 variants on herd immunity is discussed, whereby higher herd immunity threshold would be needed for arresting their circulation, whilst this in turn could be more difficult to achieve due to their stronger “resistance” to the current generation of vaccines.
...
...

References

SHOWING 1-10 OF 11 REFERENCES
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
TLDR
The safety and immunogenicity data from this U.S. phase 1 trial of two vaccine candidates in younger and older adults support the selection of BNT162b2 for advancement to a pivotal phase 2–3 safety and efficacy evaluation.
SARS-CoV-2 vaccines in development
TLDR
The development of vaccines against SARS-CoV-2 is reviewed, including an overview of the development process, the different types of vaccine candidate, and data from animal studies as well as phase I and II clinical trials in humans.
A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity
TLDR
It is shown that a recombinant vaccine that comprises residues 319–545 of the RBD of the spike protein induces a potent functional antibody response in immunized mice, rabbits and non-human primates as early as 7 or 14 days after the injection of a single vaccine dose.
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
TLDR
The mRNA-1273 vaccine induced anti-SARS-CoV-2 immune responses in all participants, and no trial-limiting safety concerns were identified, which support further development of this vaccine.
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
TLDR
In a dose-escalation study of the COVID-19 RNA vaccine BNT162b1 in 45 healthy adults, RBD-binding IgG concentrations and SARS-CoV-2 neutralizing titres in sera increased with dose level and after a second vaccine dose.
Single-Shot Ad26 Vaccine Protects Against SARS-CoV-2 in Rhesus Macaques
TLDR
Robust single-shot vaccine protection against SARS-CoV-2 in nonhuman primates is demonstrated and vaccine-elicited neutralizing antibody titers correlated with protective efficacy, suggesting an immune correlate of protection.
ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques
TLDR
It is shown that the adenovirus-vector-based vaccine ChAdOx1 nCoV-19, which encodes the spike protein of SARS- CoV-2, is immunogenic in mice and elicites a robust humoral and cell-mediated response.
COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
TLDR
The robust RBD-specific antibody, T cell and favourable cytokine responses induced by the BNT162b1 mRNA vaccine suggest that it has the potential to protect against COVID-19 through multiple beneficial mechanisms.
Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate
TLDR
The development of vaccines against SARS-CoV-2 would be greatly facilitated by the identification of immunological correlates of protection in humans, as the presence of neutralizing antibodies from prior infection was significantly associated with protection against reinfection.
Correlates of Protection Induced by Vaccination
  • S. Plotkin
  • Biology
    Clinical and Vaccine Immunology
  • 2010
TLDR
This paper attempts to summarize current knowledge about immune responses to vaccines that correlate with protection, finding some vaccines have no true correlates, but only useful surrogates, for an unknown protective response.
...
...